Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110]
Titel:
Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110]
Auteur:
Ghobrial, Irene M. Rodríguez-Otero, Paula Koh, Youngil Martínez-López, Joaquín Parmar, Gurdeep Prince, Miles Quach, Hang de la Rubia, Javier Hermansen, Emil Hungria, Vania Kalayoglu Besisik, Sevgi Kim, Jin Seok Leleu, Xavier Peceliunas, Valdas Schjesvold, Fredrik Dubin, Franck Devisme, Christine Lepine, Lucie Macé, Sandrine Oprea, Corina Mateos, María-Victoria